ESR1 and breast carcinoma: Tamoxifen, the leading drug for treating ER/PR+ breast cancer, has been clinically used for over 30 years, significantly enhancing patient prognosis and reducing breast cancer recurrence by 40% and mortality by 31% [3–6].